aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street
BLSB 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  2. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klotho
  3. Dysregulated GPCR signaling and therapeutic options in uveal melanoma
  4. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  5. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
  6. Triple jeopardy for people with albinism
  7. The melanoma field with dendritic roots
  8. The state of melanoma: challenges and opportunities
  9. Targeting mutant NRAS signaling pathways in melanoma
  10. Of Mice and melanoma: PDX system for modeling personalized medicine
  11. Welcome to the New Year!
  12. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASĀ Melanoma
  13. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  14. Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
  15. PAX3 and FOXD3 promote CXCR4 expression in melanoma
  16. RAC1 P29S regulates PD-L1 expression in melanoma
  17. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
  18. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  19. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  20. Game of isoforms: PI3K Ī²-sparing inhibitor is coming